

### Paratyphoid Fever Due to *Salmonella enterica* Serotype Paratyphi A

**To the Editor:** An outbreak of paratyphoid fever caused by *S. Paratyphi A* occurred during September and October 1996 in a residential area of New Delhi, India.

*S. Paratyphi A* has been responsible for 3% to 17% of cases of enteric fever in India (1). We suspected an outbreak because the *S. Paratyphi A* isolation rates exceeded the expected frequency based on the blood culture-positive rates from the cases of enteric fever reported by the Department of Microbiology at the All India Institute of Medical Sciences, New Delhi, the previous September and October (nine cases in 1995, 36 cases in 1996).

Thirty-six cases of culture-positive enteric fever due to *S. Paratyphi A* were reported on the basis of blood cultures received by the Department of Microbiology at the All India Institute of Medical Sciences Hospital, New Delhi, during September and October 1996. All the patients lived in the same residential area of 428 homes. The male to female ratio was 2:1, and most cases were in young adults (mean age = 20.1 yrs). All patients had a history of fever of 3 to 5 days' duration. The first culture-confirmed case was reported on September 12, 1996. After the initial case, 14 cases were reported in week 1, 10 cases in week 2, five cases in week 3, three cases in week 4, two cases in week 5, and two in week 6. Four households reported two cases each; the rest reported only one case per household. All the patients responded to ciprofloxacin treatment. All the isolates were sensitive to chloramphenicol, amoxicillin, cotrimoxazole, ciprofloxacin, gentamicin, and ceftriaxone. All the strains belonged to phage type 1.

The first suspected source of infection was contaminated food because two important Hindu festivals were celebrated on August 28 and September 5, 1996, respectively, just before the first culture-positive report on September 12. Investigators visited the affected households and distributed a questionnaire regarding demographic information, history of fever, food consumption from a common source, festival attendance, and type of water supply used. All the household contacts were also questioned. The information gathered did not indicate a foodborne outbreak. The second suspected source of infection was the water supply. The residential area receives water intermittently from a central reservoir. The

water and sewage pipelines lie close to each other; the sewer line has many joints close to the water pipes, so the water may become contaminated with human excreta from the sewer line. New Delhi had a heavy rainfall toward the end of August and the beginning of September 1996, which led to waterlogging in the residential area. The contaminated soil might have entered the water pipes (because of negative pressure inside the pipes created by intermittent water supply) and contaminated the water supplied to these households. Water samples from these households during the last week of September did not contain fecal coliform. Soil samples from different sites did not contain salmonellae. Since *S. typhi* does not survive long in the environment, isolating the organism from the source is difficult by the time the outbreak is suspected (2). This may also be true for *S. Paratyphi A*.

An outbreak of enteric fever due to *S. Paratyphi A* has never been reported. Although we could not isolate the organism from the water or the soil by the time the outbreak was suspected, epidemiologic evidence suggests a waterborne outbreak.

**Arti Kapil, Seema Sood, V.P. Reddaiah,  
Bimal Das, and Pradeep Seth**  
All India Institute of Medical Sciences,  
New Delhi, India

#### References

1. Saxena SN, Sen R. *Salmonella* Paratyphi A infection in India-Incidence and phage types. *Trans Roy Soc Trop Med Hyg* 1966;603:409-11.
2. Smith GR. Enteric infections: typhoid and paratyphoid fever. In: Wilson G, Miles A, Parker MT, editors. *Principles of bacteriology, virology and immunity*. 7th ed., vol. 3. London: Edward Arnold Ltd.; 1982. p. 407-33.

#### MHC and Infectious Diseases

**To the Editor:** The review on the importance of the major histocompatibility complex (MHC) in infectious diseases by Singh et al. (*Emerg Infect Dis* 1997;3:41-9) failed to mention the potential role of human leukocyte antigen (HLA)-DM in conferring susceptibility to infectious diseases. HLA-DM is an MHC class II-like molecule essential for normal antigen processing and presentation (1). HLA-DM has been shown to function as a peptide editor, in that it influences the repertoire of peptides bound to HLA-DR.

Furthermore, this influence occurs in an allele-specific fashion (2). In addition, HLA-DM polymorphisms have been reported to confer an increased relative risk for such varied entities as rheumatoid arthritis (3), kidney transplant rejection (4), and membranous nephropathy (5). Since HLA-DM is important in determining which peptides are immunogenic, it may be as important as MHC class II molecules in regulating the immune response and therefore in conferring susceptibility to infectious diseases.

**Victor S. Sloan**

University of Medicine and Dentistry of New Jersey  
New Brunswick, New Jersey, USA

### References

1. Busch R, Mellins ED. Developing and shedding inhibitions: how MHC class II molecules reach maturity. *Curr Opin Immunol* 1996;8:51-8.
2. Sloan VS, Zaller DM. Allelic specificity of the influence of HLA-DM on peptide repertoire. *Arthritis Rheum* 1996;39:S310.
3. Pinet V, Combe B, Avinens O, Caillat-Zucman S, Sany J, Clot J, Eliaou JF. Polymorphism of the HLA-DMA and HLA-DMB genes in rheumatoid arthritis. *Arthritis Rheum* 1997;40:854-8.
4. Chevrier D, Giral M, Bignon JD, Muller JY, Soullillou JP. Impact of the "new" MHC-encoded genes (HLA-DMA, -DMB and LMP2) on kidney graft outcome. *Hum Immunol* 1996;47:O717.
5. Giral M, Chevrier D, Muller JY, Bignon JD, Soullillou JP. TAP1\*0201 and HLA-DMA\*0103 markers and severe forms of membranous nephropathy. *Hum Immunol* 1996;47:0140.

**Reply to V.S. Sloan:** Dr. Sloan has rightly pointed out the importance of HLA-DM in regulating the immune response in rheumatoid arthritis, kidney transplant rejection, and membranous nephropathy. We did not mention the role of HLA-DM because our review dealt solely with infectious diseases that have well-established HLA associations.

**Neeloo Singh**

Central Drug Research Institute  
Lucknow, India

### Acute Epiglottitis due to *Pasteurella multocida* in an Adult without Animal Exposure

**To the Editor:** *Pasteurella multocida* infection in humans usually involves animal contact, most commonly with a domestic dog or cat (1). Epiglottitis due to human *P. multocida* infection associated with animal contact is very rare (2-4). We report a case of epiglottitis due to *P. multocida* not associated with animal contact.

A 44-year-old patient was admitted to the hospital with fever, throat fullness, and drooling. He had been healthy until 12 hours before admission when he noticed difficulty in swallowing liquids; anterior neck discomfort and fever followed, and soon he could not swallow his saliva.

When he arrived at the Emergency Department of Montefiore Medical Center on September 23, 1996, the patient was mildly toxic and had an oral temperature of 103.2°F. Pulse was 110 and blood pressure 110/70. He was drooling. He had mild anterior neck tenderness, no cervical adenopathy, no pharyngitis on inspection of the oropharynx, and no palate deviation. The heart, lungs, abdomen, and skin showed no abnormalities. A lateral neck radiograph showed an enlarged epiglottis ("thumb sign"). Indirect laryngoscopy confirmed inflamed and edematous epiglottis and supraglottic structures. A culture of the epiglottis was not performed.

On admission, the patient had a hemoglobin of 1.9 g/dL; hematocrit was 48%; white blood cell count was 14,100/mm<sup>3</sup>; and platelet count was 170,000/mm<sup>3</sup>. A machine differential count showed 86% granulocytes, 9% lymphocytes, and 5% monocytes.

The patient was treated with dexamethasone and ceftriaxone. The fever abated rapidly, and all symptoms resolved. Repeat laryngoscopy on day 3 confirmed resolving epiglottitis. Blood cultures taken on admission grew gram-negative, oxidase-positive bacilli that did not grow on MacConkey agar (BBL, Cockeysville, MD) in two sets, both aerobically and anaerobically. The isolate was identified as *P. multocida* by the Vitek GNI card (BioMérieux-Vitek, Inc., Hazelwood, MO). Kirby-Bauer susceptibility testing demonstrated susceptibility to penicillin. Because of the patient's marked improvement after treatment with

ceftriaxone and convenience of outpatient parenteral therapy, this antibiotic was continued to complete a 10-day course. On extensive questioning, the patient denied contact with any cat, dog, or other animal. He had recently traveled to Nigeria but denied even transient animal contact.

Since 1966, three cases of *P. multocida* epiglottitis have been reported (2-4). Although no direct culture of the epiglottis was performed in the present case, the clinical syndrome and the absence of any other focus accounting for *P. multocida* bacteremia strongly suggest that this organism caused the epiglottitis. Including the present case, three of the four reported cases have occurred since 1993, which suggests that either earlier cases were not recognized or the incidence of this condition may be increasing. In all three previous cases of *P. multocida* epiglottitis, the patients had cats as pets. As in the current case, the clinical features of *P. multocida* epiglottitis were indistinguishable from epiglottitis secondary to more common bacterial pathogens. However, the cases were all associated with positive blood cultures. In contrast, a 23% rate of bacteremia was reported in a series of epiglottitis cases in adults (including patients with blood cultures positive for *Haemophilus influenzae* type b or Group A streptococci)(5).

The vehicle of infection for this patient remains unknown, as human-to-human transmission has not been documented. This case demonstrates that epiglottitis due to *P. multocida*, a rare condition that may be increasing in frequency, need not be accompanied by recognized exposure to animals.

**Michael Glickman and Robert S. Klein**

Montefiore Medical Center and the Albert Einstein College of Medicine, New York, New York, USA

### References

1. Weber DJ, Wolfson JS, Swartz MN, Hooper DC. *Pasteurella multocida* infections: report of 34 cases and review of the literature. *Medicine* 1984;63:133-54.
2. Johnson RH, Rumans LW. Unusual infections caused by *Pasteurella multocida*. *JAMA* 1977;237:146-7.
3. Leung R, Jassal J. *Pasteurella* epiglottitis. *Aust N Z J Med* 1994;24:218.
4. Rydberg J, White P. *Pasteurella multocida* as a cause of acute epiglottitis. *Lancet* 1993;341:381.
5. MayoSmith MF, Hirsch PJ, Wodzinski SF, Schiffman FJ. Acute epiglottitis in adults. An eight-year experience in the state of Rhode Island. *N Engl J Med* 1986;314:1133-9.

### Hemolytic Uremic Syndrome Surveillance to Monitor Trends in Infection with *Escherichia coli* O157:H7 and Other Shiga Toxin-Producing *E. coli*

**To the Editor:** In the past 15 years, knowledge about the role of Shiga toxin-producing *Escherichia coli* (STEC) in human disease has expanded rapidly. The most distinctive complication of STEC infection is diarrhea-associated hemolytic uremic syndrome (HUS), a major cause of acute renal failure in U.S. children. Other manifestations of STEC infection can range from mild diarrhea to severe hemorrhagic colitis, thrombotic thrombocytopenic purpura, and death (1). In the United States, O157 is the most common STEC and causes an estimated 20,000 infections and 250 deaths annually. *E. Coli* O157 outbreaks associated with beef have caused concern among public health workers, clinicians, and the public, prompting major changes in clinical and laboratory practice, meat production, and food preparation. However, critical questions remain unanswered. Have prevention measures decreased risk? Are new sources of STEC infections emerging? Is the incidence of O157 infection changing? How much illness is due to STEC of serotypes other than O157?

Diarrhea-associated HUS is associated with Shiga toxin, which is produced in quantity only by STEC and by *Shigella dysenteriae* type 1; approximately 90% of HUS cases are diarrhea-associated (2,3). In the United States, where *S. dysenteriae* type 1 infections are very rare, STEC infections are the cause of virtually all diarrhea-associated HUS. The incidence of HUS in North America is about three cases per 100,000 children under 5 years of age per year; the rate among older children is somewhat lower, and the rate among adults is not known (2-6). HUS complicates approximately 5% to 10% of O157 infections and an unknown percentage of non-O157 STEC infections (1). Except for supportive care and hemodialysis, no treatment has been shown to decrease the severity of illness or to prevent complications. The sequelae of HUS—death in 3% to 5% of cases (2,3,5) and long-term renal dysfunction in 10% to 30% of survivors (6)—and the lack of specific therapy make prevention critical.

Important changes that may decrease the incidence of STEC infection and HUS in the United States are occurring now. For example, because most outbreaks of STEC infections and HUS have been linked to the consumption of undercooked beef, raw milk, or other products contaminated by the intestinal contents of cattle (1), some U.S. meat producers have changed processing practices to decrease bacterial contamination of meat. As a result of an O157 outbreak caused by consumption of frozen pre-cooked meat patties, federal regulations requiring that this product be cooked adequately to kill O157 were implemented. New requirements that raw meat be labeled with instructions for safe handling and that carcasses be tested for O157 have also recently been implemented nationwide. New vehicles of O157 transmission, for example, dry-cured salami, fermented sausage, and unpasteurized apple juice, have been discovered, prompting the reconsideration of manufacturing processes for these products. Because O157 can be transmitted from person to person (7,8), public health recommendations for control measures to prevent transmission from infected persons have been developed and disseminated (1,8). All these prevention measures show promise; however, their effectiveness has not been documented.

Other changes may not be so salutary. For instance, an increase in international trade in beef and other foods may increase exposure to non-O157 STEC in the United States. Argentina, which has a particularly high incidence of HUS (9), has recently gained approval to start exporting beef to the United States. In Australia, which also exports beef to the United States, a large outbreak of infections with Shiga toxin-producing *E. coli* O111:NM in 1995 was linked to a sausage product; in this outbreak, 23 children became ill with HUS, and one died (10).

Current surveillance methods are unlikely to detect the impact of any of these changes because of two fundamental problems. The first is that changing rates of reported O157 infections and outbreaks do not necessarily reflect actual changes in O157 incidence; it is impossible to tell how much of the marked increase in these reports may be due to greater awareness of rather than actual increase in the incidence of infection. As the public health importance of O157 has become clear, many states have attempted to improve surveillance by mandating reporting of O157 infections. Between 1987 and February 1997, the

number of states requiring such reporting increased from 3 to 42 (CDC, unpub. data). In both 1994 and 1995, 32 outbreaks were reported to CDC, the largest numbers ever, bringing the total number of reported U.S. outbreaks to 102; these comprised 2,806 illnesses and 23 deaths (CDC, unpub. data). Both heightened clinician awareness and changes in laboratory stool screening practices (11) have dramatically improved recognition of O157 infections, which has clear public health benefits. For example, if clinical laboratories in Nevada had been screening stool specimens routinely for O157 in 1993, one of the largest clusters of O157 infections ever investigated in the United States might have been recognized and controlled more quickly (12). On the other hand, changing rates of ascertainment of these infections means that O157-based surveillance systems have not been able to show trends in incidence and may not be able to do so reliably in the future.

The second fundamental problem is that surveillance for O157 infections cannot detect trends in non-O157 STEC infections. Non-O157 STEC are not likely to be detected by plating stool specimens on sorbitol-MacConkey agar (13), the method most commonly used to screen for O157. This screening test is based on the fact that, unlike most *E. coli*, very few O157 strains ferment sorbitol rapidly; since most other STEC do ferment sorbitol, this test does not detect them. Yet the non-O157 STEC pose a threat to public health in the United States. Non-O157 STEC, including *E. coli* O111:NM and *E. coli* O104:H21, have caused recent outbreaks detected only because of unusual circumstances. Similarly, sorbitol-positive O157, which recently caused a large outbreak in Germany (pers. comm. Dr. Andrea Ammon, Robert Koch Institute, Germany), would not be detected by current screening practices. In other countries, such as Australia (10) and Argentina (9), non-O157 STEC infections appear to be more common than O157 infections, and in Germany, non-O157 STEC have replaced O157 as the STEC most commonly isolated in HUS cases since 1989 (14). As travel and international trade in food increase, Americans' risk of exposure to these other STEC also increases. However, even major non-O157 STEC outbreaks might not be detected by current U.S. surveillance.

To address these two fundamental problems with current surveillance, the Centers for Disease Control and Prevention has recently initiated

active HUS surveillance in sentinel sites, which include Connecticut, Georgia, Minnesota, Oregon, and Alameda County, California and which may be expanded in the future. HUS cases, identified by a definition designed for surveillance (15), in persons under 18 years of age will be prospectively identified through referrals to pediatric nephrologists; these sites have fairly well-defined population bases, so estimating the incidence rate of pediatric HUS will be possible. Including adult HUS may be possible in the future. Because HUS is a distinctive and serious illness, its diagnosis is not likely to be affected by the first surveillance problem, the vagaries of clinical and laboratory practices that can make interpreting O157 isolation data difficult; ascertainment will likely be fairly complete. Therefore, unlike O157-based surveillance, HUS-based surveillance will allow monitoring of trends in the incidence of STEC infection and the examination of the impact of prevention efforts and changing or emerging routes of exposure. HUS cases identified through surveillance are being linked to microbial diagnosis, by culturing patients' stool for O157 and, after screening stool for Shiga toxin-producing colonies, for non-O157 STEC (in the future sera may be tested for O157 or other STEC infections). This linkage will address the second surveillance problem—by differentiating illness caused by the various STEC, linked microbial diagnosis will allow detection of trends in the incidence of non-O157 STEC as well as O157. Because passive surveillance for HUS, which has been conducted by many states and continues on a national level, lacks the microbial diagnostic component of the active surveillance system, it cannot show these trends. Active surveillance for HUS will be an efficient approach to STEC surveillance because essentially all patients with diarrhea-associated HUS have STEC infections—HUS is a more potent indicator than any other clinical syndrome.

This surveillance effort can provide the framework for future investigations in several areas. Clinical and immunologic risk factors for HUS following O157 infection could be defined through case-control studies using as controls patients with O157 infection but without HUS. Risk factors for infection with non-O157 STEC could be characterized. Serum collected from patients with non-O157 STEC infections could be used to develop serologic tests for infection with these organisms. Methods for Shiga toxin identification

in stool could be evaluated. Finally, HUS treatments could be evaluated in a well-defined patient population and study network.

Reliable surveillance data are critical to targeting prevention efforts and defining their success. A national HUS surveillance system will provide the information needed to measure the impact of new and changing vehicles of STEC transmission, evaluate the effectiveness of prevention measures, and detect illness caused by non-O157 STEC.

**Barbara E. Mahon,\* Patricia M. Griffin,† Paul S. Mead,† Robert V. Tauxe†**

\*UMDNJ-Robert Wood Johnson Medical School,  
New Brunswick, New Jersey, USA;

†Centers for Disease Control and Prevention,  
Atlanta, Georgia, USA

### References

1. Griffin PM. *Escherichia coli* O157:H7 and other enterohemorrhagic *Escherichia coli*. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, editors. *Infections of the gastrointestinal tract*. New York: Raven Press, Ltd., 1995. p. 739-61.
2. Martin D, MacDonald K, White K, Soler J, Osterholm M. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. *N Engl J Med* 1990;323:1161-7.
3. Rowe PC, Orrbine E, Wells GA, McLaine PN, Members of the Canadian Pediatric Kidney Disease Reference Center. Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. *J Pediatr* 1991;119:218-24.
4. Kinney J, Gross T, Porter C, Rogers M, Schonberger L, Hurwitz E. Hemolytic-uremic syndrome: a population-based study in Washington, DC and Baltimore, Maryland. *Am J Public Health* 1988;78:64-5.
5. Tarr PI, Hickman RO. Hemolytic uremic syndrome epidemiology: a population-based study in King County, Washington, 1971 to 1980. *Pediatrics* 1987;80:41-5.
6. Siegler R, Pavia A, Christofferson R, Milligan M. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. *Pediatrics* 1994;96:35-40.
7. Rowe PC, Orrbine E, Ogborn M, Wells GA, Winther W, Lior H, McLaine PN. Epidemic *Escherichia coli* O157:H7 gastroenteritis and hemolytic-uremic syndrome in a Canadian Inuit community: intestinal illness in family members as a risk factor. *J Pediatrics* 1994;124:21-6.
8. Belongia E, Osterholm M, Soler J, Ammend D, Braun J, MacDonald K. Transmission of *Escherichia coli* O157:H7 infection in Minnesota child day-care facilities. *JAMA* 1993;269:883-8.
9. Lopez EL, Diaz M, Grinstein S, Devoto S, Mendilaharsu F, Murray BE, et al. Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. *J Infect Dis* 1989;160:469-75.
10. Goldwater PN, Bettelheim KA. An outbreak of hemolytic uremic syndrome due to *Escherichia coli* O157:H7: or was it? *Emerg Infect Dis* 1996;2:153-4.

## Letters

11. Boyce TG, Pemberton AG, Wells JG, Griffin PM. Screening for *Escherichia coli* O157:H7—a nationwide survey of clinical laboratories. *J Clin Microbiol* 1995;33:3275-7.
12. Cieslak PR, Noble SJ, Maxson DJ, Empey LC, Ravenholt O, Legarza G, et al. Hamburger-associated *Escherichia coli* O157:H7 infection in Las Vegas: a hidden epidemic. *Am J Public Health* 1997;87:176-80.
13. March SB, Ratnam S. Sorbitol-MacConkey medium for detection of *Escherichia coli* O157 associated with hemorrhagic colitis. *J Clin Microbiol* 1986;23:869-72.
14. Huppertz H, Busch D, Schmidt H, Aleksic S, Karch H. Diarrhea in young children associated with *Escherichia coli* non-O157 organisms that produce Shiga-like toxin. *J Pediatr* 1996;128:341-6.
15. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. *MMWR Morb Mortal Wkly Rep* 1997;46:17.